TEMPLATE DESIGN © 2008 www.PosterPresentations.com Negative LLETZ following severe dyskaryosis: a curious phenomenon Üçyiğit A, Jones M H, Dutta A, El.

Slides:



Advertisements
Similar presentations
Normal cervix, cervical TZ and how to dissect a LLETZ
Advertisements

Which women are having a Hysterectomy and why? A plain English presentation of the methodology and findings of a database linkage study Dr Helen Stokes-Lampard.
MANAGEMENT OF ABNORMAL PAP SMEAR
OPTIONAL LOGO HERE Prevalence of endometrial cancer in symptamatic women with thickened endometrium Dr Maheswari SRINIVASAN MRCOG SpR, Mrs Shagaf BAKOUR.
AUDIT OF COMPLIANCE WITH NHSCSP GUIDELINES REQUIRING MDT REVIEW OF ALL CERVICAL CANCER PATIENTS Dr. M Bhattacharjee Dr. A Mutton Dr. S Nagarajan.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Detection of human telomerase gene (TERC) amplification in cervical neoplasia: A retrospective study of 79 patients Pap smear slides Renarta Crookes Sheffield.
Updates on Pap Smear Guidelines 2014
Sample Taker Training Cervical Cytology & Management of Abnormalities.
Comparison of HPV Testing and Spectroscopy Combined with Cytology for the Detection of High- grade Cervical Neoplasia C Werner, W Griffith III, R Ashfaq,D.
COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
HPV and cervical screening Test of cure
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Benign and premalignant disease of the cervix
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Case Presentations: Pre-Invasive Cervical Neoplasia
COLPOSCOPY Cervical Screening QARC Training School October 2012.
AN AUDIT OF PAP SMEAR, COLPOSCOPY AND HISTOLOGY RESULTS FROM IN TUNGARU CENTRAL HOSPITAL (KIRIBATI)
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
Cervical Sample Taker Training 2015 THE NHS CERVICAL SCREENING PROGRAMME (NHSCSP)
PATTERN OF GYNAECOLOGICAL MALIGNANCIES IN DELTA STATE UNIVERSITY TEACHING HOSPITAL,OGHARA:A 2 YEAR REVIEW. MOFON C EBEIGBE P.E ABEDI H.O DELSUTH.
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Objectives Tubal factor is an important criteria in the investigation of sub-fertile couples. Hysterosalpingography (HSG) is one of the frequently used.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
NHS Cervical Screening Programme, England, : Graphs.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Cervical Intraepithelial Neoplasm
Colposcopy & Research.  Arch Gynecol Obstet May 26. [Epub ahead of print] Arch Gynecol Obstet.  Risk factors for treatment failure following cold.
TEMPLATE DESIGN © Outcome of Large Loop Excision of Transformation Zone (LLETZ ) in women over forty at two London Hospitals.
TEMPLATE DESIGN © Objectives Methods This was a retrospective cohort data analysis of all women who presented with menorrhagia.
Sheffield Gynaecological Cancer CentreSheffield Teaching Hospitals PRIMARY HPV SCREENING A view from colposcopy John Tidy Consultant Gynaecological Oncologist.
1 Cervical Screening Programme, England, : Graphs.
Premalignant lesions of the cervix. Applied anatomy.
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
NHS Cervical Screening Programme, England, : Graphs.
Appendix 2 Comparison of screening from age 20 and age 25 Table of harms and benefits.
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
The Natural History of Benign Thyroid Nodules JAMA. 2015;313(9): doi: /jama Modulator Prof. 전숙 / R1 윤수진.
Cervical cancer screening and treatment among HIV+ women in Cambodia: feasible and high yielding M.-E. Raguenaud 1, P. Isaakidis 1, S.A. Khim 1, C. Ping.
ELIGIBILITY CRITERIA- Summarised
Understanding Test Results
Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,
Trreatment of Preinvasive Lesions
Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın
Quality issues in monitoring diagnostic and treatment performance Dr
Operative Approach and
Cytology Codes & management Colposcopy- Management of cervical lesions
Cervical Cancer Colposcopy & Treatment
Cervical Screening Programme, England, : Graphs
Efficacy of random cervical biopsy and routine endocervical curettage in subjects with normal colposcopy.
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Dr N Shailaja Dr Pradeep
An Audit of Colposcopy Practice on Mild Dyskaryosis or Borderline Changes on Cervical Smear and the Effectiveness of “See & Treat” vs. Biopsy and Recall.
NHS Cervical Screening Programme, England : Graphs
SBÜ KAYSERİ ERH Doç. Dr. Gökhan Açmaz
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
Cervical Screening for Dysplasia and Cancer in Patients with HIV
SH-sheikhhasani Gyn-oncologist
Downgrading -IN 2, Diagnoses and Predicting Higher-grade Lesions
SCC MDT Service Evaluation
Presentation transcript:

TEMPLATE DESIGN © Negative LLETZ following severe dyskaryosis: a curious phenomenon Üçyiğit A, Jones M H, Dutta A, El Sayed M, Dugmore W E, Thomas V, Carter P G Darent Valley Hospital, Dartford, Kent, United Kingdom. St George’s Hospital, London, United Kingdom Objectives Large loop excision of the transformation zone (LLETZ) is a standard treatment for suspected cervical intraepithelial neoplasia grade III and provides histological confirmation of the diagnosis. Since the introduction of LLETZ a worrying phenomenon has been observed, whereby there is negative histology on LLETZ despite a confirmed diagnosis of severe dyskaryosis on the referral cervical smear. The incidence of this problem has been reported as anywhere between 20% and 34% of all LLETZ biopsies regardless of the grade of referral cytology. 1,2 There is little available data for severe dyskaryosis specifically. The objective of this study was to identify the incidence of negative LLETZ following a cytological diagnosis and treatment of severe dyskaryosis, and to explore why this may occur. Methods A retrospective review of the electronic colposcopy database ‘View Point’ was conducted over a eight year period. The study was conducted in two clinical settings: a teaching hospital in London and a district general hospital in Kent, St. George’s Hospital (SGH), and Darent Valley Hospital (DVH) respectively. All women who had severe dyskaryosis on referral with a negative histology result after LLETZ were included. The incidence of negative LLETZ and the rates of negative and abnormal cytology after LLETZ were compared between the two centres. A supplementary retrospective study was undertaken in the district general hospital setting over the subsequent three years from the completion date of the main study (2008 to 2011 inclusive). Results A total of 62 patients with negative LLETZ were identified from a population of 1152 with severe dyskaryosis. Of these, 41 cases were at SGH, and 21 at DVH (6.6% vs. 4.0%) which was not statistically significant (Table 1). Table 2 shows the proportion of patients with negative cytology on follow-up: 85% vs. 62% (SGH vs. DVH). Conversely, table 3 shows the proportion of patients with abnormal cytology on follow-up: 10% vs. 5%, and further treatment was performed in 10% and 19% of patients at SGH and DVH respectively. Table 4 compares the incidence of negative LLETZ following a referral with severe dyskaryosis at DVH in the initial and supplementary studies. This was not found to be significantly different from the previous result (p=0.7). * Difference not significant at 5% level but significant at 6.6% (exact test) An explanation for negative LLETZ was identified in 5 cases: 4 cases of high endocervical disease were confirmed following hysterectomy, and one case of vaginal cancer was identified. No explanation was found for the remaining patients. Conclusions References The finding of negative LLETZ despite severe dyskaryosis on referral cytology is an uncommon, yet curious event. There was however no demonstrable difference in incidence between the teaching hospital and district general hospital settings and there appears to be a low risk of missing malignancy. A small proportion of patients demonstrated recurrent abnormal cytology on follow-up. This lack of correlation between histological and cytological results may be explained by current histological sampling techniques (how the specimens are sliced), where small-volume high grade lesions may not be revealed. It is interesting to note that the findings of the supplementary study performed three years after the initial work showed a remarkably similar incidence of negative LLETZ following referral with severe dyskaryosis. This consistency of findings makes it still the more difficult to explain how this clinical situation arises. Despite the recommendation that nearly all LLETZ specimens should contain CIN, this has not been achieved in the majority of colposcopy units. 3 What follow-up regime, and ultimately treatment is best employed in these cases requires further investigation. 1. Skehan M, Soutter WP, Lim K, Krausz T, Pryse- Davies J. Reliability of colposcopy and directed punch biopsy. Br J Obstet Gynaecol Sep;97(9): Lopes A, Pearson SE, Mor-Yosef S, Ireland D, Monaghan JM. Is it time for a reconsideration of the criteria for cone biopsy? Br J Obstet Gynaecol.1989 Nov;96(11): Semple D, Saha A, Maresh M. Colposcopy and treatment of cervical intra-epithelial neoplasia: are national standards achievable? Br J Obstet Gynaecol Apr;106(4): Acknowledgement: We would like to thank Dr J J Jones for his help with statistical analysis. Table 1: Negative LLETZ after severe dyskaryosis HospitalNegative LLETZConfidence limits SGH n = 416.6%(4.6 – 8.5) DVH n = 214%(2.3 – 5.7) Difference*2.6%(-0.2 – 5) Table 2: Negative smear after LLETZ HospitalNegative smearConfidence limits SGH85%(71 – 94) DVH62%(38 – 82) Difference23%(0 – 49) Table 3: Abnormal cytology after LLETZ HospitalAbnormal smearConfidence limits SGH10%(3 – 23) DVH5%(0.1 – 24) Difference5%(-13 – 17) Table 4: Supplementary study StudyNegative LLETZConfidence limits DVH %(2.3 – 5.7) DVH n = 7/232 3%(1 – 5)) Difference-1%(+2 – -4)